Kannalife Sciences, Inc. is a biopharmaceutical company dedicated to the research and development of innovative cannabinoid therapeutics aimed at addressing significant unmet medical needs, particularly in the areas of inflammation, neurodegeneration, and neuropathic pain. The company has developed a proprietary product platform featuring novel CBD-like molecules, with its lead candidate, KLS-13019, demonstrating enhanced potency, safety, and bioavailability compared to traditional CBD. KLS-13019 is being investigated for its potential to treat conditions such as chemotherapy-induced peripheral neuropathy (CIPN) and hepatic encephalopathy (HE), leveraging its neuroprotective properties to offer non-opioid alternatives for pain management.

Kannalife has made significant strides in securing intellectual property rights, including multiple patents for its cannabinoid-derived compounds, which bolster its position in the competitive landscape of cannabinoid therapeutics. The company has received substantial funding from organizations like the Michael J. Fox Foundation and the National Institutes of Health to support its research initiatives. Through rigorous preclinical studies, Kannalife aims to validate the efficacy of KLS-13019 and its related molecules in treating a range of neurodegenerative disorders, including Alzheimer's and Parkinson's disease, while also exploring their potential applications in managing oxidative stress-related conditions.

United States

Kannalife Sciences, Inc. (a subsidiary of Neuropathix, Inc.) is a biopharmaceutical company focused on the research and development of a pipeline of next-generation pharmaceutical and phyto-medical products. The company is based in Doylestown, Pennsylvania and is known for its globally patented anti-inflammatory technology. Kannalife Sciences, Inc. is dedicated to the development of breakthrough therapeutics targeted for the treatment of inflammation and neurodegenerative diseases.

Kannalife Sciences, Inc.

Company Details